Please assess the completion status of the following clinical trial:

Trial Title: 5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* histological diagnosis of well-differentiated neuroendocrine carcinoma according to the World Health Organization (WHO) classification;~* locally advanced or metastatic disease not amenable to surgery with radical intent;~* at least one measurable target lesion;~* radiological documentation of progressive disease;~* ECOG performance status grade \<=2;~* life expectancy \>12 weeks;~* adequate bone marrow reserve;~* adequate hepatic and renal function;~* ability to comply with the protocol procedures (including geographic accessibility);~* written informed consent.~Exclusion Criteria:~* non-malignant systemic disease or conditions that precluded patients from receiving the study therapy;~* second primary malignancies and previous systemic antineoplastic treatment including somatostatin analogues;~* history of prior malignancy, excepted for cured non-melanoma skin cancer, and cured in situ cervical carcinoma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- treatment arm (Type: EXPERIMENTAL): continuous 5 fluouracil infusion plus long-acting octreotide

Based on this trial design, predict the completion outcome and termination type (if applicable).